MicroProbe Corp. of Bothell, Wash., on Thursday said it wasawarded a $50,000 Small Business Innovation Research (SBIR)grant from the National Institutes of Health to study thecommercial feasibility of an antisense therapeutic that wouldcleave the targeted DNA of a virus or other infectiousorganisms.

EARNINGS REPORTS

GENZYME INCREASES REVENUES, DEEPENS LOSS

Genzyme Corp. (NASDAQ:GENZ) of Cambridge, Mass., said its netloss for the quarter includes a $9.1 million write-off of theappraised value of Genzyme warrants granted in connectionwith the financing of Neozyme and the associatedadministrative expenses. Losses for the year were offset by again of $7.2 million from the sale of common stock by IGLaboratories, a Genzyme subsidiary, the company said.

Fourth quarter ended Dec. 31

(Figures in thousands except per-share data.)

1990 1989 Percent change

Revenues $18,554 11,162 +66Operating expenses $18,351 13,337 +38Operating profit (loss) 203 (2,175) +109Net income (loss) (8,847) (5,834) -52Net income per share (loss) (.55) (.48) -15Outstanding shares 16,116 12,096 +33

Year ended Dec. 31

(Figures in thousands except per-share data.)

1990 1989 Percent change

Revenues $54,835 34,285 +60Operating expenses $59,377 39,989 +48Operating profit (loss) (4,542) (5,704) +20Net income (loss) (27,161) (13,016) -109Net income per share (loss) (1.70) (1.32) -29Outstanding shares 15,944 9,855 +62

ECOGEN LOWERS LOSS FOR QUARTER, YEAR

Ecogen Inc. (NASDAQ:EECN) of Langhorne, Pa., reported afourfold increase in product sales in the fourth quarter. John E.Davies, company chairman and chief executive officer, said,"With the growth in sales forecast for 1991, coupled with themarketing and R&D agreements signed in January withRoussel-UCLAF AND 3A, totaling about $15 million over fouryears, we expect to substatntially cut our losses in 1991,"

Fourth quarter ended Dec. 31

(Figures in thousands except per-share data.)

1990 1989 Percent change

Revenues $646 599 +8Operating expenses 2,499 2,780 -10Net income (loss) (2,063) (2,223) +7Net income per share (loss) (.18) (.33) +45Outstanding shares 11,756 6,678 +76

Year ended Dec. 31

(Figures in thousands except per-share data.)

1990 1989 Percent change

Revenues $2,188 2,939 -26Operating expenses 9,548 10,715 -11Net income (loss) (7,968) (8,179) +3Net income per share (loss) (.88) (1.22) +29Outstanding shares 9,014 6,680 +35

NOVA INCREASES REVENUES, DEEPENS LOSS

Nova Pharmaceutical Corp. (NASDAQ:NOVX) of Baltimore.

Fourth quarter ended Dec. 31

(Figures in thousands except per-share data.)

1990 1989 Percent change

Revenues $14,036 4,004 +251Net income (loss) (4,230) (3,993) -6Net income per share (loss) (.16) (.15) -7Outstanding shares 26,758 26,618 neg.

Year ended Dec. 31

(Figures in thousands except per-share data.)

1990 1989 Percent change

Revenues $36,095 15,698 +130Net income (loss) (14,245) (12,688) -12Net income per share (loss) (.53) (.48) -10Outstanding shares 26,723 26,612 neg.

(c) 1997 American Health Consultants. All rights reserved.

No Comments